Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 4, 2012, Pages 585-591

  Ohr, Matthew ^a   Kaiser, Peter K ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Aflibercept; Age related macular degeneration; Choroidal neovascularization; Eylea; Fusion protein; Placental growth factor; Trap; VEGF

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; EYLEA; PEGAPTANIB; RANIBIZUMAB; UNCLASSIFIED DRUG; VERTEPORFIN;

ANGIOGENESIS; COLON CANCER; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; EXUDATIVE MACULAR DEGENERATION; FOOD AND DRUG ADMINISTRATION; HEALTH INSURANCE; HUMAN; HYPERTENSION; OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; PROSPECTIVE STUDY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION; VISUAL ACUITY;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; NEOVASCULARIZATION, PATHOLOGIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT FUSION PROTEINS;

EID: 84857250733     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.658368     Document Type: Review

References (45)

1. Resnikoff S, Pascolini D, Etya'ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ 2004;82:844-51 (Pubitemid 39573742)
2. Waisbourd M, Loewenstein A, Goldstein M, et al. Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration. Drugs Aging 2007;24:643-62
3. Folk JC, Stone EM. Ranibizumab therapy for neovascular age-related macular degeneration. N Engl J Med 2010;363:1648-55
4. Bhise NS, Shmueli RB, Sunshine JC, et al. Drug delivery strategies for therapeutic angiogenesis and antiangiogenesis. Expert Opin Drug Deliv 2011;8:485-504
5. Klein R, Wang Q, Klein BE, et al. The relationship of age-related maculopathy, cataract, and glaucoma to visual acuity. Invest Ophthalmol Vis Sci 1995;36:182-91
6. Argon laser photocoagulation for senile macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 1982;100:912-18
7. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy. Three-year results from randomized clinical trials. Arch Ophthalmol 1986;104:694-701
8. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Arch Ophthalmol 1991;109:1109-14
9. Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: One-year results of 2 randomized clinical trials - TAP report. Arch Ophthalmol 1999;117:1329-45
10. Bressler NM; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol 2001;119:198-207 (Pubitemid 32147926)
11. Bressler NM, Arnold J, Benchaboune M, et al. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report no. 3. Arch Ophthalmol 2002;120:1443-54 (Pubitemid 36406418)
12. Azab M, Benchaboune M, Blinder KJ, et al. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: treatment of age-related macular degeneration with photodynamic therapy and verteporfin in photodynamic therapy study report no. Retina 2004;24:1-12
13. Blumenkranz MS, Bressler NM, Bressler SB, et al. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials - TAP report no. 5. Arch Ophthalmol 2002;120:1307-14 (Pubitemid 36105436)
14. Kaiser PK; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension: TAP report no. 8. Graefes Arch Clin Exp Ophthalmol 2006;244:1132-42 (Pubitemid 44269592)
15. Spilsbury K, Garrett KL, Shen WY, et al. Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization. Am J Pathol 2000;157:135-44 (Pubitemid 30641731)
16. Tischer E, Mitchell R, Hartman T, et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991;266:11947-54
17. Kourlas H, Schiller DS. Pegaptanib sodium for the treatment of neovascular age-related macular degeneration: a review. Clin Ther 2006;28:36-44 (Pubitemid 43254988)
18. Gragoudas ES, Adamis AP, Cunningham ET, et al. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-16 (Pubitemid 40051904)
19. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31 (Pubitemid 44511557)
20. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-44 (Pubitemid 44511558)
21. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009;116:57-65.e5
22. Kourlas H, Abrams P. Ranibizumab for the treatment of neovascular age-related macular degeneration: a review. Clin Ther 2007;29:1850-61 (Pubitemid 350214458)
23. Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005;112:1035-47 (Pubitemid 40797459)
24. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:331-5 (Pubitemid 41073112)
25. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006;26:383-90 (Pubitemid 44197628)
26. Steinbrook R. The price of sight - ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med 2006;355:1409-12 (Pubitemid 44511554)
27. Martin DF, Maguire MG, Ying GS, et al. CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-908
28. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1. Am J Ophthalmol 2008;145:239-48
29. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143:566-83
30. Holz FG, Amoaku W, Donate J, et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology 2011;118:663-71
31. Spaide R. Ranibizumab according to need: a treatment for age-related macular degeneration. Am J Ophthalmol 2007;143:679-80 (Pubitemid 46452536)
32. Aflibercept: AVE 0005, AVE 005, AVE0005, VEGF trap-regeneron, VEGF trap (R1R2), VEGF trap-eye. Drugs R D 2008;9:261-9
33. Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF trap. Br J Ophthalmol 2008;92:667-8 (Pubitemid 351684178)
34. Holash J, Davis S, Papadopoulos N, et al. VEGF-trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002;99:11393-8 (Pubitemid 34920936)
35. Nguyen QD, Shah SM, Hafiz G, et al. A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006;113:1522-e1,1522.e14
36. Dixon JA, Oliver SC, Olson JL, et al. VEGF trap-eye for the treatment of neovascular age-related macular degeneration. Expert Opin Investig Drugs 2009;18:1573-80
37. Nguyen QD, Shah SM, Browning DJ, et al. A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration. Ophthalmology 2009;116:2141-8.e1
38. Brown DM, Heier JS, Ciulla T, et al. Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration. Ophthalmology 2011;118:1089-97
39. Heier JS, Boyer D, Nguyen QD, et al. The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing. Ophthalmology 2011;118:1098-106
40. Vascular endothelial growth factor (VEGF) trap-eye: investigation of efficacy and safety in wet age-related macular degeneration (VIEW1). 2011, updated 4 May. Available from http:// clinicaltrials.gov/ct2/show/NCT00509795 [last accessed 30 December 2011]
41. Vascular endothelial growth factor (VEGF) trap-eye: investigation of efficacy and safety in wet age-related macular degeneration (VIEW 2). 2011, updated 6 June. Available from http:// clinicaltrials.gov/ct2/show/NCT00637377 [last accessed 30 December 2011]
42. Heier JS. VEGF trap-eye phase III trial results. VIEW 1 results. Presented at Angiogenesis, exudation, and degeneration; 12 February 2011; Miami, FL, USA
43. Schmidt-Erfurth U. VEGF trap-eye phase III trial results. VIEW 2 results. Presented at Angiogenesis, exudation, and degeneration; 12 February 2011; Miami, FL, USA
44. Tseng JJ, Vance SK, Della Torre KE, et al. Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. J Glaucoma 2011; Epub ahead of print
45. FDA alerts health care professionals of infection risk from repackaged avastin intravitreal injections. 2011, updated 30 August. Available from http://www. fda.gov/Drugs/DrugSafety/ucm270296. htm [last accessed 30 December 2011]